SYDNEXIS
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.
SYDNEXIS
Industry:
Manufacturing Pharmaceutical
Founded:
2014-01-01
Address:
Del Mar, California, United States
Country:
United States
Website Url:
http://www.sydnexis.com
Total Employee:
11+
Status:
Active
Contact:
(619) 507-9827
Email Addresses:
[email protected]
Total Funding:
50.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager Google Analytics Content Delivery Network LetsEncrypt
Similar Organizations
Acceleron Pharma
Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Longitude Capital
Longitude Capital investment in Series B - Sydnexis
Medicxi
Medicxi investment in Series B - Sydnexis
Bluestem Capital
Bluestem Capital investment in Series B - Sydnexis
Visionary Venture Fund
Visionary Venture Fund investment in Series B - Sydnexis
RA Capital Management
RA Capital Management investment in Series B - Sydnexis
SC Master Fund
SC Master Fund investment in Series B - Sydnexis
Medicxi
Medicxi investment in Venture Round - Sydnexis
RA Capital Management
RA Capital Management investment in Venture Round - Sydnexis
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-16 | Perry J. Sternberg Joins Sydnexis as Chief Executive Officer |
| 2023-08-29 | Sydnexis Welcomes Nick Ruth as Chief Commercial Officer |
Official Site Inspections
http://www.sydnexis.com Semrush global rank: 11.44 M Semrush visits lastest month: 162
- Host name: cloudhost-5007599.us-west-1.nxcli.net
- IP address: 173.249.147.247
- Location: Southfield United States
- Latitude: 42.4593
- Longitude: -83.2207
- Metro Code: 505
- Timezone: America/Detroit
- Postal: 48075
More informations about "Sydnexis"
About Sydnexis
Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD …See details»
Sydnexis Inc.
Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD-101, in a Phase 3 clinical trial to …See details»
Sydnexis - Crunchbase Company Profile & Funding
Organization. Sydnexis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Sydnexis is …See details»
Management at Sydnexis
Sydnexis may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, …See details»
Sydnexis - Funding, Financials, Valuation & Investors - Crunchbase
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Working Toward an Approved Pharmacological …
Dec 16, 2024 Perry Sternberg brings to Sydnexis over 30 years of commercial leadership, including oversight of more than 20 product launches across a wide range of therapeutic areas and markets. His tenure in eye care spans 15 …See details»
Sydnexis, Inc. | TREA
OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF. Publication number 20230381016; Publication date Nov 30, 2023; Sydnexis, Inc. Gregory I. OstrowSee details»
Sydnexis, Inc. Company Profile | Del Mar, CA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Sydnexis, Inc. of Del Mar, CA. Get the latest business insights from Dun & Bradstreet.See details»
Sydnexis 2025 Company Profile: Valuation, Funding
Sydnexis General Information Description. Developer of a eyecare medicine and drug designed to treat myopia. The company offers a topical eyedrop formulation used to treat the progression of myopia in children, enabling medical …See details»
Sydnexis - LinkedIn
Sydnexis | 1,235 followers on LinkedIn. We focus on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic. | Myopia is the most common eye disease ...See details»
Sydnexis - VentureRadar
Sydnexis is a privately held clinical stage biopharmaceutical company developing a proprietary formulation for decreasing myopic progression in children. Sydnexis has developed a novel, …See details»
Sydnexis Company Profile - Office Locations, Competitors ... - Craft
Sydnexis is a clinical-stage biopharmaceutical company developing a proprietary formulation for decreasing myopic progression in children. It offers SYD-101, an eyedrop formulation.See details»
Contact Us - Sydnexis
445 Marine View Avenue, Suite 295 Del Mar, Ca 92014 858-925-6172 [email protected] Sydnexis may use and disclose online usage data about you collected automatically through …See details»
Sydnexis Announces FDA Acceptance of New Drug ... - Business Wire
Mar 11, 2025 Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of …See details»
Sydnexis - Contacts, Employees, Board Members, Advisors & Alumni
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. …See details»
Sydnexis, Top BioTech Startup-2023 - pharmatechoutlook.com
Sydnexis has been recognized as Top 10 BioTech Startups – 2023 by Pharmatech. ... Bausch & Lomb, and Shire where he was responsible for the U.S. commercial organization and …See details»
FDA Accepts New Drug Application for Sydnexis’ SYD-101
March 11, 2025 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Sydnexis’ SYD-101 for myopia management. The agency …See details»
Sydnexis welcomes Perry J. Sternberg as Chief Executive Officer
DEL MAR, CA - July 16, 2024 – Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company focused on the treatment of progression of pediatric myopia, is …See details»
Inside the MOA of SYD-101, the potential first FDA-approved …
1 day ago The recent FDA acceptance of the new drug application for atropine 0.01% (SYD-101, Sydnexis) marks a significant milestone in the field of myopia management, and Paul …See details»
Sydnexis Announces FDA Acceptance of New Drug Application …
DEL MAR, Calif. - March 11, 2025 – Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration …See details»